PyInvesting

Market research

ALCLS.PA Cellectis S.A

Current ticker: ALCLS.PA

PA EUR Healthcare

Latest close

0.98 —

As of Nov 19, 2026

Test a moving-average rule with historical data.

Market facts

Market cap
106M
P/E ratio
Not available
Analyst target
6.5
Dividend yield
Not available
Beta
2.94

Community

Investor discussion

1 comment

Admin profile picture
Admin

Apr 1, 2021

Cellectis S.A is currently in a long term downtrend where the price is trading 33.0% below its 200 day moving average.

From a valuation standpoint, the stock is 95.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 11.8.

Cellectis S.A's total revenue rose by 213.8% to $14M since the same quarter in the previous year.

Its net income has dropped by 5.6% to $-39M since the same quarter in the previous year.

Finally, its free cash flow fell by 838.0% to $-52M since the same quarter in the previous year.

Based on the above factors, Cellectis S.A gets an overall score of 2/5.